IκB kinase-β inhibitor IMD-0354 beneficially suppresses retinal vascular permeability in streptozotocin-induced diabetic mice

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 10, 2014, Pages 6365-6373

  Lennikov, Anton ^a   Hiraoka, Miki ^a   Abe, Akira ^a   Ohno, Shigeaki ^b   Fujikawa, Tomoyuki ^c   Itai, Akiko ^c   Ohguro, Hiroshi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Institute of Medicinal Molecular Design (IMMD) Inc   (Japan)

Author keywords

Diabetes; IKK 2; IKK ; IMD 0354; Inflammation; NF B; Retina

Indexed keywords

CASPASE 3; DIMETHYL SULFOXIDE; I KAPPA B KINASE INHIBITOR; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; BENZAMIDE DERIVATIVE; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE; N-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-5-CHLORO-2-HYDROXYBENZAMIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RETINA BLOOD VESSEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD RETINA BARRIER; C57BL MOUSE; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DISEASE COURSE; DRUG EFFECTS; METABOLISM; MOUSE;

ANIMALS; BENZAMIDES; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE PROGRESSION; I-KAPPA B KINASE; MALE; MICE; MICE, INBRED C57BL; RETINAL VESSELS;

EID: 84908110008     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14671     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.
2. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19:442–455.
3. Adamis AP, Aiello LP, D’Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis. 1999;3:9–14.
4. Watkins PJ. ABC of diabetes – retinopathy. BMJ. 2003;326:924–926.
5. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–358.
6. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NFkappaB- dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinasedefective form of the IkappaB kinase 2. J Cell Sci. 2003;116: 665–674.
7. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetesinduced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci. 2007;48:4342–4350.
8. Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia. 1999;42:603–607.
9. Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 1999;42:728–736.
10. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes. 2002;51:2241–2248.
11. Shin JY, Sohn J, Park KH. Chlorogenic acid decreases retinal vascular hyperpermeability in diabetic rat model. J Korean Med Sci. 2013;28:608–613.
12. Zandi E, Chen Y, Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science. 1998;281:1360–1363.
13. Yamaoka S, Courtois G, Bessia C, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell. 1998;93: 1231–1240.
14. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7:758–765.
15. Cahir-McFarland ED, Carter K, Rosenwald A, et al. Role of NFkappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol. 2004;78:4108–4119.
16. Lamberti A, Romano MF, Agosti V, et al. Regulation of cell survival in CD95-induced T cell apoptosis: role of NF-kappa B/ Rel transcription factors. Apoptosis. 1999;4:179–186.
17. Karin M. The NF-kappa B activation pathway: its regulation and role in inflammation and cell survival. Cancer J Sci Am. 1998;4(suppl 1):S92–S99.
18. Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D. NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci. 2003;6:1072–1078.
19. Inayama M, Nishioka Y, Azuma M, et al. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 2006;173: 1016–1022.
20. Sugita A, Ogawa H, Azuma M, et al. Antiallergic and antiinflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. Int Arch Allergy Immunol. 2009;148:186–198.
21. Onai Y, Suzuki J, Kakuta T, et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;63:51–59.
22. Matsumoto N, Ariga A, Toe S, et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 2000;10:865–869.
23. Kamon J, Yamauchi T, Muto S, et al. A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem Biophys Res Commun. 2004;323: 242–248.
24. Lennikov A, Kitaichi N, Noda K, et al. Amelioration of endotoxin-induced uveitis treated with an IkappaB kinase beta inhibitor in rats. Mol Vis. 2012;18:2586–2597.
25. Essani NA, Fisher MA, Jaeschke H. Inhibition of NF-kappa B activation by dimethyl sulfoxide correlates with suppression of TNF-alpha formation, reduced ICAM-1 gene transcription, and protection against endotoxin-induced liver injury. Shock. 1997;7:90–96.
26. Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994;43:1326–1333.
27. Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol. 2005; 175:6257–6263.
28. Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia. 2010;53:971–979.
29. Lu H, Lu Q, Gaddipati S, et al. IKK2 inhibition attenuates laserinduced choroidal neovascularization. PLoS One. 2014;9: e87530.
30. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor- 1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A. 2000;97:12222–12226.
31. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998;273:8225–8231.
32. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–1070.